COVID-19 and immune checkpoint inhibitors: initial considerations.

Sullivan RJ, Johnson DB, Rini BI, Neilan TG, Lovly CM, Moslehi JJ, Reynolds KL
J Immunother Cancer. 2020 8 (1)

PMID: 32434790 · PMCID: PMC7246104 · DOI:10.1136/jitc-2020-000933

MeSH Terms (9)

Antineoplastic Agents, Immunological Coronavirus Infections COVID-19 Humans Molecular Targeted Therapy Neoplasms Pandemics Pneumonia, Viral Programmed Cell Death 1 Receptor

Connections (2)

This publication is referenced by other Labnodes entities:

Links